Allogene Therapeutics (ALLO) said Monday that the US Food and Drug Administration granted three fast track designations for ALLO-329, which the company is developing to treat autoimmune diseases.
The designations cover the treatment of adult patients with active refractory moderate-to-severe systemic lupus erythematous, active severe or refractory idiopathic inflammatory myopathy, and active refractory diffuse systemic sclerosis (Scleroderma), according to the company.
Allogene said FDA's fast track designation is intended to expedite the development and review of therapies that address serious or life-threatening conditions and demonstrate the potential to meet unmet medical needs.
The company said it plans to start a phase 1 trial of ALLO-329 in the diseases covered by the three fast track designations in mid-2025, with proof-of-concept from the trial expected by the end of the year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。